Improvements in ACQ-7 and AQLQ scores
and other secondary end points in these two
replicate trials were small and inconsistent and
did not reach the minimal clinically important
difference; in light of the fact that episodes of
asthma worsening were reduced significantly,
this modest symptomatic benefit was surprising.